[Cefsulodine concentrations in cerebral ventricles during parenteral treatment of ventriculitis due to Pseudomonas aeruginosa (author's transl)].
Cefsulodine, a new B-lactamase-resistant cephalosporin, was used parenterally in combination with systemic and topical tobramycin to treat a patient with meningitis and ventriculitis due to Os, aeruginosa. Cefsulodine concentrations were measured simultaneously in serum and in cerebral ventricles. With doses of 500 mg four times a day, diffusion of the drug into meningeal spaces was rather poor, but with doses of 2 grams 8-hourly (100 mg/Kg/day cefsulodine concentrations in the ventricles were equal or superior to the average MICs against most Pseudomonas species. However, concurrent systemic and local administration of an aminoglycoside is required to ensure full bactericidal effect.
D002441:Cefsulodin; D002511:Cephalosporins / Q000378:metabolism* / Q000627:therapeutic use; D002552:Cerebral Ventricles / Q000378:metabolism*; D004660:Encephalitis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002441:Cefsulodin
Concentrations de la cefsulodine dans les ventricules cérébraux lors du traitement par voie génŕale d'une ventriculite à Pseudomonas aeruginosa.